Monday , 24 June 2024

A Systematic Review of Desvenlafaxine’s Efficacy, Safety, Moa, and Adverse Effects in the Treatment of Major Depressive Disorders

Narendra Kumar Reddy Kolli*1, Swetha Polagani1, Bharghava Bhushana Rao Pathange2
1Sri Vani School of Pharmacy, Chevuturu, Vijayawada, AP. India
2VVIPS, Gudlavalleru, Krishna Dt, AP, India

A  B S T R A C T
Desvenlafaxine (DVS) was a novel serotonin (5-HT) that was currently in clinical development for the treatment of major depressive disorder and vasomotor symptoms associated with menopause. Desvenlafaxine was originally synthesized as part of research project to discover structural analogs of 4-(2-(Dimethylamino)-1-(hydroxycyclohexy) ethyl phenol is the major active metabolite of the antidepressant, a medication used to treat major depressive, generalized anxiety and panic disorders. Literature survey revealed that few LC-MS methods have been reported for estimation of DVS in biological matrices.

Keywords: Desvenlafaxine, serotonin (5-HT), antidepressant

Scroll To Top